Raguneprocel

N/A

Report date: 2025/12/25 15:59:19

Base Information

Drug NameRaguneprocel
Drug Alias NameAllogeneic iPS [induced pluripotent stem] cell-derived dopaminergic neural progenitor cells therapy(Sumitomo Chemical)CT1-DAP001DSP1083DSP-1083
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Somatic cell > Dopaminergic neural orogenitor cell therapyCell and gene therapy > Cell therapy > Source of cells > iPSC-derived
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSumitomo Chemical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSumitomo Pharma America IncSumitomo Chemical Co Ltd
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A